GlassScriptPhysician profile
Lynnette M Khandaker
NPI 1396292421
$3,559.58
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.26 · 2022: $1,870 · 2023: $1,554 · 2024: $90.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,533.08 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.19 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $590.53 | 2021-2023 | Invega Sustenna, Spravato |
| Alkermes, INC. | $387.24 | 2021-2023 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $339.22 | 2022-2023 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $317.78 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $299.16 | 2022-2024 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $289.43 | 2022-2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $286.32 | 2022-2024 | Ingrezza |
| Corium, LLC | $109.60 | 2022-2023 | Azstarys |
| Axsome Therapeutics, INC. | $94.52 | 2022-2023 | Auvelity |
| Merck Sharp & Dohme LLC | $55.48 | 2022-2023 | Belsomra |
| Indivior INC. | $49.04 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.84 | 2022 | |
| Lundbeck LLC | $27.89 | 2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $24.45 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $19.54 | 2023 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $13.68 | 2023 | Quviviq |
| Eisai INC. | $13.05 | 2022 | |
| Mayne Pharma Commercial LLC | $7.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynnette Khandaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.